follow-up colorectal cancer Carcinoembryonic Antigen
Conditions
Interventions
After randomization at hospital level, all patients in that hospital will participate in the new follow-up scheme. This consists of increasing of the frequency of CEA measurement, and of performing an
Sponsors
Univeristy Medical Center Groningen
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with stage II- III –IV colorectal carcinoma after curative resection (R0 resection) from 1-1-2007; 2. All new patients with II-III-IV colorectal carcinoma eligible for curative resection; 3. Patients currently in follow-up, operated within 2 years after start study; 4. All patients need to be above 18 and capable of understanding the Dutch language.
Exclusion criteria
Exclusion criteria: 1. Patients with other malignancies except basocellular carcinoma of the skin; 2. Patients not medically fit for metastasectomy; 3. Patients with diagnosed syn- or metachronous incurable metastases at time of start study; 4. No written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The percentage of curatively treatable recurrent or metachronous metastatic disease in the intervention group in comparison with the control group. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Disease free survival, recurrent-free survival, overall survival; 2. Quality of Life in patients undergoing more intensified follow-up schemes; 3. Costs and effectiveness of introducing a software tool to support the frequent CEA measrurements. | — |
Contacts
Public ContactC. Verberne
Hanzeplein 1
Outcome results
None listed